Search

Izzat T Raheem

from Doylestown, PA
Age ~46
Get Report
Also known as:
Izzat Kaheem, Izzat Raheen
Phone and address:
4401 Sunflower Dr, Gardenville, PA 18902
Related to:
Hussein Hersi Hassan
Connected to:
Adam Raheem, 36Akeem F Raheem, 40Habeeb S Raheem, 74I Raheem, 68Kamal R Raheem, 37Khalil A Raheem, 35Muhammad Raheem, 66Muslimah Raheem, 44Nefertiti A Raheem, 44Robert A Raheem, 75

Izzat Raheem Phones & Addresses

  • 4401 Sunflower Dr, Doylestown, PA 18902
  • Philadelphia, PA
  • 16 Shepard St, Cambridge, MA 02138 (617) 764-2497
  • Warminster, PA
  • 2170 Parker Ln, Yorktown Heights, NY 10598
  • Buck, PA
  • New York, NY
  • Pittsburgh, PA
  • 1206 Spring St, Warminster, PA 18974 (617) 548-6896

Work

Company: Merck & co., inc. Aug 2012 Address: West Point, PA Position: Associate principal scientist

Education

Degree: Ph.D. School / High School: Harvard University 2002 to 2007 Specialities: Organic Chemistry

Skills

Organic Synthesis • Drug Discovery • Organic Chemistry • Medicinal Chemistry • Drug Design • Pharmaceutical Industry • Hplc • Drug Development • Chemistry • Synthetic Organic Chemistry • Purification • Nmr • Lead Change • Lc Ms • Biotechnology • Chromatography • Life Sciences

Languages

English • Danish • French

Emails

i***[email protected]

Industries

Pharmaceuticals

Resumes

Resumes

Izzat Raheem Photo 1

Director

View page
Location:
4401 Sunflower Dr, Doylestown, PA 18902
Industry:
Pharmaceuticals
Work:
Merck & Co., Inc. - West Point, PA since Aug 2012
Associate Principal Scientist
Merck & Co., Inc. - West Point, PA Jul 2011 - Aug 2012
Research Fellow
Merck & Co., Inc. - West Point, PA Sep 2007 - Jul 2011
Senior Research Chemist
Harvard University 2002 - 2007
Graduate Student
Education:
Harvard University 2002 - 2007
Ph.D., Organic Chemistry Carnegie Mellon University 1996 - 2000
B.S., Chemistry/Computer Science
Skills:
Organic Synthesis
Drug Discovery
Organic Chemistry
Medicinal Chemistry
Drug Design
Pharmaceutical Industry
Hplc
Drug Development
Chemistry
Synthetic Organic Chemistry
Purification
Nmr
Lead Change
Lc Ms
Biotechnology
Chromatography
Life Sciences
Languages:
English
Danish
French

Publications

Us Patents

Alkoxy Tetrahydro-Pyridopyrimidine Pde10 Inhibitors

View page
US Patent:
8492392, Jul 23, 2013
Filed:
May 24, 2010
Appl. No.:
13/320038
Inventors:
Michael J. Breslin - Drexel Hill PA, US
Paul J. Coleman - Harleysville PA, US
Christopher D. Cox - Harleysville PA, US
Izzat T. Raheem - Doylestown PA, US
John D. Schreier - Harleysville PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/519
US Classification:
5142641, 544279, 544353, 546113, 546118, 546119, 5462681, 5483351, 5483731
Abstract:
The present invention is directed to alkoxy tetrahydro-pyridopyrimidine compounds of formula I, which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

2,5-Disubstituted Piperidine Orexin Rceptor Antagonists

View page
US Patent:
20110201632, Aug 18, 2011
Filed:
Oct 15, 2009
Appl. No.:
13/124901
Inventors:
Michael J. Breslin - Harleysville PA, US
Paul J. Coleman - Harleysville PA, US
Christopher D. Cox - Harelysville PA, US
Izzat T. Raheem - Philadelphia PA, US
Anthony J. Roecker - North Wales PA, US
John D. Schreier - Philadelphia PA, US
International Classification:
A61K 31/517
C07D 215/233
A61K 31/47
C07D 215/38
C07D 413/14
A61K 31/454
C07D 495/04
A61K 31/4365
C07D 401/14
A61K 31/4545
C07D 471/02
A61K 31/4375
A61P 25/00
A61P 3/04
US Classification:
51426622, 546153, 514312, 546162, 514313, 546198, 514321, 546114, 514301, 546194, 514318, 546122, 514300, 544284
Abstract:
The present invention is directed to 2,5-disubstituted piperidine amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

7-Aza-Quinazoline Pde10 Inhibitors

View page
US Patent:
20110319409, Dec 29, 2011
Filed:
Jun 23, 2010
Appl. No.:
12/821311
Inventors:
Christopher D. Cox - Harleysville PA, US
Izzat T. Raheem - Philadelphia PA, US
Broc A. Flores - Ardmore PA, US
David B. Whitman - Phoenixville PA, US
International Classification:
A61K 31/5377
A61P 25/18
A61P 25/28
A61P 25/00
A61K 31/519
C07D 471/04
US Classification:
5142342, 51426411, 544117, 544279
Abstract:
The present invention is directed to 7-aza-quinazoline compounds of general structural formula Iwhich are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10).

Amino Tetrahydro-Pyridopyrimidine Pde10 Inhibitors

View page
US Patent:
20120136012, May 31, 2012
Filed:
Aug 5, 2010
Appl. No.:
13/389270
Inventors:
Michael J. Breslin - Drexel Hill PA, US
Paul J. Coleman - Harleysville PA, US
Christopher D. Cox - Harleysville PA, US
Izzat T. Raheem - West Point PA, US
John D. Schreier - Philadalphia PA, US
Assignee:
Merck Sharp & Dohme Corp - Rahway NJ
International Classification:
A61K 31/519
C07D 519/00
A61P 25/18
A61P 25/28
A61P 25/14
C07D 471/04
A61P 25/22
US Classification:
51426411, 544279
Abstract:
The present invention is directed to amino tetrahydro-pyridopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Aryl Aminopyridine Pde10 Inhibitors

View page
US Patent:
20120196856, Aug 2, 2012
Filed:
Oct 26, 2010
Appl. No.:
13/501130
Inventors:
Michael J. Breslin - Drexel Hill PA, US
Christopher D. Cox - Harleysville PA, US
Izzat T. Raheem - North Wales PA, US
International Classification:
A61K 31/5377
C07D 401/14
A61K 31/497
C07D 471/04
A61K 31/4375
A61P 25/22
A61K 31/4725
C07D 471/14
A61K 31/4709
A61K 31/437
A61P 25/00
A61P 25/18
C07D 413/14
A61K 31/444
US Classification:
5142345, 544124, 5142355, 544405, 51425505, 546122, 514300, 546264, 514332, 544127, 546144, 514307, 546 82, 514293, 546176, 514314, 544128, 5142352, 546113
Abstract:
The present invention is directed to aryl aminopyridine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pyrazolopyrimidine Pde 10 Inhibitors

View page
US Patent:
20130137707, May 30, 2013
Filed:
Sep 26, 2011
Appl. No.:
13/816568
Inventors:
Christopher D. Cox - Harleysville PA, US
Izzat T. Raheem - Doylestown PA, US
John D. Schreier - West Point PA, US
International Classification:
A61K 31/519
C07D 487/04
US Classification:
5142593, 544281
Abstract:
The present invention is directed to pyrazolopyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Pro Drugs Of Pde10 Compounds

View page
US Patent:
20220306619, Sep 29, 2022
Filed:
Mar 15, 2022
Appl. No.:
17/695125
Inventors:
- Rahway NJ, US
Jason W. Skudlarek - Audubon PA, US
Izzat T. Raheem - Doylestown PA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 417/14
Abstract:
The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Amido-Substituted Heterocyclic Compounds And Methods Of Use Thereof For The Treatment Of Herpes Viruses

View page
US Patent:
20230077499, Mar 16, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/783870
Inventors:
- Rahway NJ, US
Andrew John Cooke - Scotland, GB
Robert Patrick Hayes - Lexington MA, US
Marc A. Labroli - Moorestown NJ, US
Michael Aaron Plotkin - Frenchtown NJ, US
Izzat Tiedje Raheem - Doylestown PA, US
Jeffrey W. Schubert - North Wales PA, US
David M. Tellers - Lansdale PA, US
Assignee:
Merck Sharp & Dohme LLC - Rahway NJ
International Classification:
A61K 31/4439
C07D 413/06
C07D 413/14
A61K 31/517
A61K 31/538
A61K 31/4725
A61K 31/4709
A61P 31/22
A61K 45/06
Abstract:
The present invention relates to novel Amido-Substituted Heterocycle Compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein X, R, R, R, and Rare as defined herein. The present invention also relates to compositions comprising at least one Amido-Substituted Heterocycle Compound, and methods of using the Amido-Substituted Heterocycle Compounds for treating or preventing a herpesvirus infection in a patient.
Control profile
Izzat T Raheem from Doylestown, PA, age ~46 Get Report